Which statement is incorrect about NPH insulin?

NORCET 10 Mains

Pharmacology

Easy

Appeared in: NORCET 10 Mains

Explanation

The statement that NPH insulin is given by the IV route is incorrect.
NPH insulin is a suspension (it appears cloudy) containing protamine, which delays its absorption.
Administering a suspension intravenously can cause particulate matter to travel through the bloodstream, leading to a potentially fatal embolism (blood vessel blockage).
Only clear insulins, such as Regular (short-acting) and rapid-acting analogues (lispro, aspart), are approved for intravenous administration.

Option B: This is a correct statement. The formulation of NPH insulin as a suspension is specifically designed for slow and prolonged absorption from the subcutaneous tissue.
Option C: This is a correct statement. All insulins carry a risk of hypoglycemia, which is most pronounced when the insulin's effect is at its peak. For NPH, this occurs between 4 and 12 hours after injection.
Option D: This is a correct statement. NPH insulin is classified as intermediate-acting based on its onset of action (1-4 hours), peak effect (4-12 hours), and duration (10-20 hours).

Visual 1: Chart - A comparative chart of different insulin types (Rapid, Short, Intermediate, Long-acting) showing their appearance (clear vs. cloudy), onset, peak, and duration times. This helps visualize why NPH is intermediate-acting.
Visual 2: Diagram - A step-by-step illustration of how to mix insulins, demonstrating the 'clear before cloudy' principle (drawing up Regular insulin before NPH insulin). This reinforces the physical difference between the insulin types.

Clinical Relevance

Nursing practice connection: This is primarily an exam-oriented knowledge point with limited direct bedside application, so retain Pharmacology and administration of NPH insulin as background academic context rather than a clinical decision trigger.
A fundamental nursing safety principle is knowing which medications can be administered via which route. Mistakenly giving NPH insulin intravenously is a critical medication error with severe consequences.
Patient education must include the signs and symptoms of hypoglycemia (e.g., sweating, shakiness, confusion) and how to manage it, especially during the insulin's peak action time.
What if? If a patient with diabetes requires emergency treatment for diabetic ketoacidosis (DKA), the nurse would anticipate orders for an intravenous infusion of Regular (short-acting) insulin, not NPH, to rapidly correct hyperglycemia and ketosis.

How to Approach the Question

First, identify the negative framing of the question. You are looking for the statement that is FALSE or INCORRECT.
Recall the key characteristics of NPH insulin. It is an 'intermediate-acting' insulin, it looks 'cloudy' because it's a suspension, and it is given 'subcutaneously'.
Evaluate each option against these core facts.
Option A suggests IV administration. Remember the rule: cloudy insulins (suspensions) are never given IV. Only clear insulins (solutions) like Regular insulin can be given intravenously. This makes statement A incorrect.
Confirm that the other options are correct statements: NPH is given subcutaneously only (True), it can cause hypoglycemia at its peak (True), and it is classified as intermediate-acting (True).
Since the question asks for the incorrect statement, select the option that is factually wrong.

Concept Tested & Keywords

Q2QK8u85q1OJtVhwAHnHB8